India, March 3 -- Apogee Therapeutics, Inc. (APGE) Monday announced positive interim results from Phase 1 study of APG990.
The study is the first-in-human trial evaluating the safety, tolerability and pharmacokinetic (PK) of APG990 in healthy adult participants. APG990 demonstrated a potential best-in-class PK profile, including a half-life of about 60 days, supporting the potential for every three- and six-month maintenance dosing.
The results support potential for the company's planned combination study of APG777 and APG990, called APG279.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Apogee plans to submit an Investigational New Drug application or foreign equivalent for APG279. Following cleara...